



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com


www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)



Elacestrant-d₄

Cat. No.:	HY-19822S
Molecular Formula:	C ₃₀ H ₃₄ D ₄ N ₂ O ₂
Molecular Weight:	462.66
Target:	Isotope-Labeled Compounds; Estrogen Receptor/ERR
Pathway:	Others; Vitamin D Related/Nuclear Receptor
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Elacestrant-d ₄ (RAD1901-d ₄) is deuterated labeled Elacestrant (HY-19822) Elacestrant (RAD1901) is an orally available and selective estrogen receptor degrader (SERD) with IC ₅₀ s of 48 and 870 nM for ERα and ERβ, respectively. Elacestrant also can inhibit growth of ER ⁺ breast cancer cell lines in vitro and in vivo.
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother*. 2019;53(2):211-216.
- [2]. Bihani T, et al. Elacestrant (RAD1901), a Selective Estrogen Receptor Degradar (SERD), Has Antitumor Activity in Multiple ER⁺ Breast Cancer Patient-derived Xenograft Models. *Clin Cancer Res*. 2017 Aug 15;23(16):4793-4804.
- [3]. Garner F, et al. RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models. *Anticancer Drugs*. 2015 Oct;26(9):948-56.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA